Generic Applications Sample Clauses

Generic Applications. A team of two applications developers/users will be based in Italy and also supported by the other partners, in particular the Central Europe Federation, with the specific remit of working to identify general and particularly new applications on the EGEE infrastructure. These two partners are in close contact with many research communities, eager to deploy their applications on the Grid. In Germany, Fraunhofer-Gesellschaft, the leading organization of institutes of applied research and development in Europe will work together with the partners of NA4 to identify and migrate general and new industrial relevant applications for use on the EGEE Infrastructure. DKRZ provides state-of-the-art supercomputing, data service and other associated services to the national and international scientific community to conduct top of the line earth system and climate modeling. In NA4 the role of DKRZ is identification and adaptation of early user applications from earth system research. In the Netherlands, FOM will apply to EGEE all the expertise gained within the DataGrid project to support applications coming from earth observations and astronomy. These participants will be complemented by participants from across the remainder of Europe with a broad remit to identify encourage the use of applications from a number of their local academic and industry sectors. These funded participants will be complemented by commensurate unfunded effort from each of the above partners and from the collection of national initiatives from across Europe represented by the EGEE I3. Funded participants: XXXX will lead this effort with a funded allocation of 2FTE. Central Europe, Germany, Northern Europe with 1 funded FTE each will complement the effort as described above. Unfunded participants: Each funded partner will contribute the same unfunded manpower to the task. In addition, for each selected application, a dedicated team will be identified within that community to start deploying this application on EGEE infrastructure.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Generic Applications. Although High Energy Physics and Biomedical Applications, discussed above, are the two most important “customers” of the EGEE infrastructure, and their feed-back is essential for the re-engineering and fine tuning of the middle-ware services, the success of the Project strongly relies on the use of the continental infrastructure also by other different applications, belonging both to science and industry realms, which we address here as generic applications. On this purpose, we will also seek to cooperate with existing Framework 5 funded projects to deploy their applications on the EGEE infrastructure. For example, the CrossGrid project has deployed and extended the EU DataGrid software for interactive compute and data intensive applications such as simulation and visualisation for surgical procedures, flooding crisis, team decision support systems, and air pollution combined with weather forecasting. These application areas and user communities are obvious candidates for extending the scope of applications that will be early exploiters of the EGEE Grid infrastructure. We will then undertake the following specific activities: • organization of dissemination and tutoring events to spread the grid paradigm and attract people from science and industry. These activities are under the responsibility of the NA2/NA3 teams, with which a close liaison will be established; • selection of applications to be ported onto the EGEE infrastructure, in a gradual and orderly manner; • support the development community to migrate their generic applications to the EGEE infrastructure using high level user interfaces such as grid portals; • evaluation of grid impact on generic application performances.
Sample 1Sample 2See All (4)
Generic Applications. Leveraging on the experience gained within the DataGrid project, experts of the selected applications will be put in contact with the developers of the GENIUS grid portal in Italy, with stages of a few days (maximum 1 week), in order to learn how to build the graphic user interface between the given generic application and the available grid services. The tools used for this work will evolve according to the developments in the common application software. As above, the institutes involved with the selected generic applications will be encouraged to dedicate part of their resources to become an EGEE node. Care will be taken to include in EGEE those grid facility sites having adequate support for middleware installation and maintenance. Training sessions will be organized in connection with Networking Activity 3.
Sample 1Sample 2Sample 3
Generic Applications. During the migration of generic applications to the EGEE infrastructure, a continuous feed-back will be given to the middle-ware developers, especially pointing out missing features. Important developments are expected in the common applications interface which aims at hiding the details of interfacing to grid services from the user. It is expected that important advances will be made as this software is adapted to the needs of the end user in various areas, these resulting from the feedback to the developers of both the common applications interface and the underlying middleware. In addition an aim is to aid the applications to develop application specific interfaces using common tools.
Sample 1Sample 2Sample 3
Generic Applications. AP-DVA-9805 (Application) AP-DVA-2001 (Application) AP-DVA-2001C (Core Application) AP-DVA-2001SS (Short Surrender Charge Application) AP-DVA-2001B (Bonus Application) AP-DVA-2001Z (No Surrender Charge Application)
Sample 1
Generic Applications. Once the applications are selected, the proposing institutes will be invited to carry on with their deployment on the EGEE infrastructure. On this purpose, leveraging on the experience gained within the DataGRID project, experts of the various generic applications will be put in contact with the developers of the GENIUS grid portal in Italy, with stages of a few days (max 1 week), in order to learn how to build the graphic user interface between the given generic application and the available grid services. As above, the institutes involved with the selected generic applications will be encouraged to dedicate part of their resources to become an EGEE node. Care will be taken to include in EGEE grid facility sites having adequate support for middleware installation and maintenance. Training sessions will be organized in connection with Networking Activity 3.
Sample 1
Generic Applications. Once the generic applications are selected, the proposing institutes will be invited to carry on with their deployment on the EGEE infrastructure. A significant fraction of the resources allocated to this activity will be devoted to supporting the migration of these new applications and to the customization of high level user interfaces to help new users to use them. In this respect, in order to hide the new inexperienced users from the complexity of the system and details of the actual implementations, we will make use of the great experience gained so far by INFN with the GENIUS grid portal (xxxxx://xxxxxx.xx.xxxx.xx), developed in conjunction with NICE srl within the context of the DataGRID Project. During the migration of generic applications to the EGEE infrastructure, a continuous feed-back will be given to the middle-ware developers, especially pointing out missing features.
Sample 1
AutoNDA by SimpleDocs

Related to Generic Applications

  • Regulatory Applications (a) Sky and Metropolitan and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare, within 45 days of the execution of this Agreement, all documentation and requests for regulatory approval, to timely effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities and Regulatory Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Sky and Metropolitan shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, and shall be provided in advance so as to reasonably exercise its right to review in advance, all material written information submitted to any third party or any Governmental Authority or Regulatory Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities or Regulatory Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.

  • Third Party Applications Oracle or third party providers may offer Third Party Applications. Except as expressly set forth in the Estimate/Order Form, Oracle does not warrant any such Third Party Applications, regardless of whether or not such Third Party Applications are provided by a third party that is a member of an Oracle partner program or otherwise designated by Oracle as “Built For NetSuite,” "certified," "approved" or “recommended.” Any procurement by Customer of such Third Party Applications or services is solely between Customer and the applicable third party provider. Customer may not use Third Party Applications to enter and/or submit transactions to be processed and/or stored in the NetSuite CPQ, unless Customer has procured the applicable subscription to the NetSuite CPQ for such use and access. Oracle is not responsible for any aspect of such Third Party Applications that Customer may procure or connect to through the NetSuite CPQ, or any interoperation, descriptions, promises, or other information related to the foregoing. If Customer installs or enables Third Party Applications for use with the NetSuite CPQ, Customer agrees that Oracle may enable such third party providers to access Customer Data for the interoperation of such Third Party Applications with the NetSuite CPQ, and any exchange of data or other interaction between Customer and a third party provider is solely between Customer and such third party provider pursuant to a separate privacy policy or other terms governing Customer’s access to or use of the Third Party Applications. Oracle shall not be responsible for any disclosure, modification or deletion of Customer Data resulting from any such access by Third Party Applications or third party providers. No procurement of such Third Party Applications is required to use the NetSuite CPQ. If Customer was referred to Oracle by a member of one of Oracle’s partner programs, Customer hereby authorizes Oracle to provide such member or its successor entity with access to Customer’s business information related to the procurement and use of the NetSuite CPQ pursuant to this Agreement, including but not limited to User names and email addresses, support cases and billing/payment information.

  • General Application The rules set forth below in this Article IV shall apply for the purposes of determining each Member’s general allocable share of the items of income, gain, loss or expense of the Company comprising Net Income or Net Loss of the Company for each Fiscal Year, determining special allocations of other items of income, gain, loss and expense, and adjusting the balance of each Member’s Capital Account to reflect the aforementioned general and special allocations. For each Fiscal Year, the special allocations in Section 4.4 shall be made immediately prior to the general allocations of Section 4.3.

  • Patent Applications It is understood by the parties that, pursuant to the Baylor Technology Transfer Agreement, MAS has the initial responsibility for filing, prosecution and maintenance of Patents and Patent Applications covering the Baylor Technology. The parties agree that, as between MAS and CTI, MAS shall be responsible for deciding whether and how to file, prosecute and maintain the Patents and Patent Applications, provided that:

  • Notice, Application The Agent shall have received (with, in the case of the initial Revolving Loan only, a copy for each Bank) a Notice of Borrowing or a Notice of Conversion/Continuation, as applicable or in the case of any Issuance of any Letter of Credit, the Issuing Bank and the Agent shall have received an L/C Application or L/C Amendment Application, as required under Section 3.2;

  • Territorial application As regards the Kingdom of the Netherlands, the present Agreement shall apply to the part of the Kingdom in Europe, to the Netherlands Antilles and to Aruba, unless the notification provided for in Article 14, paragraph (1) provides otherwise.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.

  • Provisional Application Upon signature of this Compact, and until this Compact has entered into force in accordance with Section 7.3, the Parties will provisionally apply the terms of this Compact; provided that, no MCC Funding, other than Compact Implementation Funding, will be made available or disbursed before this Compact enters into force.

  • Regulatory Authorizations Each Party represents and warrants that it has, or applied for, all regulatory authorizations necessary for it to perform its obligations under this Agreement.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

Time is Money Join Law Insider Premium to draft better contracts faster.